.Attribute Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin caused enhanced progression-free and total survival, causing FDA commendation as well as a new treatment option for individuals.